Exploration of prognostic value and underlying mechanism of P2RY14 in triple negative breast cancer by multi-omics

Abstract

Abstract Background Triple negative breast cancer (TNBC) was a highly heterogeneous and invasive breast cancer. Although novel therapeutic strategies had improved, it could not still achieve satisfactory efficacy. P2RY14 participated in the occurrence and development of numerous cancers, while the relationship between P2RY14 and TNBC remained uncertain. Therefore, our aim was to investigate the value of P2RY14 in TNBC to improve this condition.Method The differential expression of P2RY14 was determined based on 158 TNBC and 113 paracancer samples came from TCGA database via Wilcoxon test. The result was validated using GSE37751 and GSE65216 database. Kaplan–Meier analysis was performed to analysis and validate the relationship between P2RY14 and overall survival of TNBC in both TCGA cohort and METABRIC cohort. Patients was divided into low P2RY14 group and high P2RY14 group based the median expression value of P2RY14. Single-sample gene-set enrichment analysis and immune cycle analysis were utilized to investigate underlying mechanism.Result P2RY14 was significant differential expression with P < 0.05 among TCGA, GSE37751 and GSE65216. The methylation of P2RY14 had an inhibitory function in its expression via Pearson correlation analysis (P < 0.05). Patients with high P2RY14 had improved overall survival based on criterion of P < 0.05 in TCGA. The result was validated in METABRIC. Higher immune infiltration in 29 immune cells was mainly closely correlated with high P2RY14 group. Multiple steps of immune cycle were positively associated with High P2RY14 group. In addition, we found that immunotherapy had potential values in high P2RY14 group.Conclusion Our study elucidated the significant value of P2RY14 on pathogenesis and prognosis of TNBC and demonstrated its potential as a novel biomarker. Our results would provide novel perspectives into the prognosis monitoring and decision for TNBC.